Drugs / DPT-IPV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01926015 | Sep 2013 → Jun 2014 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02140047 Background | Apr 2014 → Jan 2015 | haemophilus infectious disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03891758 Comparator | Apr → Sep 2019 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02992925 Comparator | Nov 2016 → Dec 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPT-IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02140047 ↗ |
| Known as | DTP-IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01926015 ↗ |
| Known as | Tetrabik | “concomitant vaccination with ActHIB® (Hib) and Tetrabik (DPT-IPV) as a comparator” PMID 38582691 ↗ Apr 2024 |
| Modality | Vaccine | “Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule” NCT01926015 ↗ |
| Route | Subcutaneous | “DTP-IPV (0.5 mL subcutaneous injection)” NCT01926015 ↗ |